Melatonin and the Brain–Heart Crosstalk in Neurocritically Ill Patients—From Molecular Action to Clinical Practice
Authors:
- Artur BekałaABArtur Bekała
- Włodzimierz PłotekWPWłodzimierz Płotek
- Dorota Siwicka-GierobaDSDorota Siwicka-Gieroba
- Joanna Sołek-PastuszkaJSJoanna Sołek-Pastuszka
- Romuald BohatyrewiczRomuald Bohatyrewicz
- Jowita BiernawskaJBJowita Biernawska
- Katarzyna KotfisKKKatarzyna Kotfis
- Magdalena BielaczMBMagdalena Bielacz
- Andrzej JaroszyńskiAJAndrzej Jaroszyński
- Wojciech DabrowskiWDWojciech Dabrowski
Open Access
- 25 June 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 7094
Abstract
Brain injury, especially traumatic brain injury (TBI), may induce severe dysfunction of extracerebral organs. Cardiac dysfunction associated with TBI is common and well known as the brain–heart crosstalk, which broadly refers to different cardiac disorders such as cardiac arrhythmias, ischemia, hemodynamic insufficiency, and sudden cardiac death, which corresponds to acute disorders of brain function. TBI-related cardiac dysfunction can both worsen the brain damage and increase the risk of death. TBI-related cardiac disorders have been mainly treated symptomatically. However, the analysis of pathomechanisms of TBI-related cardiac dysfunction has highlighted an important role of melatonin in the prevention and treatment of such disorders. Melatonin is a neurohormone released by the pineal gland. It plays a crucial role in the coordination of the circadian rhythm. Additionally, melatonin possesses strong anti-inflammatory, antioxidative, and antiapoptotic properties and can modulate sympathetic and parasympathetic activities. Melatonin has a protective effect not only on the brain, by attenuating its injury, but on extracranial organs, including the heart. The aim of this study was to analyze the molecular activity of melatonin in terms of TBI-related cardiac disorders. Our article describes the benefits resulting from using melatonin as an adjuvant in protection and treatment of brain injury-induced cardiac dysfunction.Keywords
This publication has 138 references indexed in Scilit:
- Melatonin membrane receptors in peripheral tissues: Distribution and functionsMolecular and Cellular Endocrinology, 2012
- Quantitation of melatonin and n‐acetylserotonin in human plasma by nanoflow LC‐MS/MS and electrospray LC‐MS/MSJournal of Mass Spectrometry, 2012
- Ca2+/Calmodulin and Presynaptic Short-Term PlasticityISRN Neurology, 2011
- Silencing Nox4 in the Paraventricular Nucleus Improves Myocardial Infarction–Induced Cardiac Dysfunction by Attenuating Sympathoexcitation and Periinfarct ApoptosisCirculation Research, 2010
- Reactive Oxygen Species Production in Energized Cardiac Mitochondria During Hypoxia/ReoxygenationCirculation Research, 2008
- Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and bindingBlood, 2006
- Expression of membrane and nuclear melatonin receptors in mouse peripheral organsLife Sciences, 2004
- Daily Nighttime Melatonin Reduces Blood Pressure in Male Patients With Essential HypertensionHypertension, 2004
- A Novel Melatonin Metabolite, Cyclic 3-Hydroxymelatonin: A Biomarker ofin VivoHydroxyl Radical GenerationBiochemical and Biophysical Research Communications, 1998
- The effect of exogenous melatonin on the hypothalamic‐pituitary‐adrenal axis in intact and pinealectomized rats under basal and stressed conditionsJournal of Pineal Research, 1993